Floatz logo

AVOLVE

Nonmalignant Neoplasm

University of California, San FranciscoSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Nonmalignant Neoplasm cohort.

Asset / SponsorPhaseRating
Ringer's acetate
Joachim Zdolsek
Phase 4BB
NORMAL HUMAN SERUM ALBUMIN
Joachim Zdolsek
Phase 4BB
Evomela
Roswell Park Cancer Institute
Phase 2/3B
Thiotepa
Roswell Park Cancer Institute
Phase 2/3B
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2/3B

View all 16 →

Same molecule, other indications

AVOLVE is also rated in:

prostate cancerDormant
BB
Indicative ·
71 / 100
View asset →
benign prostatic hyperplasiaDormant
BB
Indicative ·
68 / 100
View asset →
erectile dysfunctionDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →